AI Enlists in Medicine to Fix Image, Warns It’s Bad at Miracles

KEY POINTS

•Anthropic CEO Dario Amodei announced rapid AI investments in biology and medicine with early results expected in months.
•Companies like Nvidia and Eli Lilly created a $1 billion drug lab, while Isomorphic Labs from Google raised $2.1 billion.
•Public concerns remain over data center expansions, AI-related job losses, healthcare costs, and potential misuse for bioweapons.

Anthropic CEO Dario Amodei just announced on X that his AI lab is sprinting into medicine with hopes of 'incredible results' imminently, though he left out the magic cure part. Meanwhile, Nvidia and Eli Lilly casually dropped a billion dollars on a San Francisco drug discovery lab where scientists and AI geeks awkwardly mix. Google’s spinoff, Isomorphic Labs, raised a casual $2.1 billion to boss-round AI and clinch top clinical talent while hookup deals with Novartis, Lilly, and Johnson & Johnson keep it fancy. All this while Americans rage 'NIMBY' over data centers, fearing AI stealing jobs and secretly plotting biological weapons—so Anthropic tacked on nuclear-level safeguards for their Claude Fable 5, in case it gets hacker-handsy. And yes, current breakthroughs might be years away, but hey, AI speeding up drug development also means more expensive healthcare because robots demand better paperwork. The Trump administration juggles hands-off policy with safety oversight, and everyday Americans still side-eye Big Pharma's drug prices. Essentially, AI must convince us it’s not just another Silicon Valley gold digger before we let server farms invade our backyards.